U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900543) titled 'Safety and Efficacy of TareSphere Injection and CTACE in Patients with Unresectable HCC' on March 17.
Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Unresectable Hepatocellular Carcinoma
Intervention:
DRUG: NRT6003 Injection
Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic ...